マトリンとその誘導体:がん治療におけるマルチパスウェイ制御
1Department of Thoracic Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, 646600, People's Republic of China.
Cancer management and research
|December 30, 2025
まとめ
マトリン誘導体は、前臨床モデルにおいて、腫瘍増殖を阻害し、耐性を克服するマルチターゲット抗がん剤として有望視されています。臨床応用への課題克服にはさらなる研究が必要です。
科学分野:
- 天然物化学;腫瘍学;薬理学
背景:
- マトリンとその誘導体は、相乗的な抗腫瘍効果が実証されているマルチターゲット天然アルカロイドです。
- これらの化合物は、Wnt/β-catenin、MAPK/ERK、PI3K/AKT/mTORなどの重要な癌原性経路を調節します。
- 上皮間葉転換(EMT)を抑制し、プログラム細胞死(アポトーシス、オートファジー、パイロトーシス)を誘導することにより、腫瘍増殖を抑制します。
研究 の 目的:
- マトリン誘導体の抗腫瘍可能性をレビューすること。
- 作用機序と前臨床有効性を強調すること。
- 臨床応用への課題と将来の方向性を特定すること。
主な方法:
- がん治療におけるマトリン誘導体の前臨床研究のレビュー。
- 癌原性経路、細胞死、腫瘍免疫微小環境への影響の分析。
- 患者由来異種移植(PDX)モデルにおける第3世代誘導体(例:MT-26、YF-18)の評価。
主要な成果:
- 第3世代マトリン誘導体は、膵臓癌および肝臓癌のPDXモデルにおいて、有意な腫瘍抑制効果(60-78%)を示しました。;これらの誘導体は、DNMT1/HDAC6の二重阻害を標的とし、NLRP3/カスパーゼ-1のパイロトーシス経路を活性化します。;化学療法耐性の克服に有効性を示しました。
結論:
- マトリン誘導体は、マルチパスウェイ制御と細胞死誘導を通じて、強力な前臨床抗がん活性を示します。
- 臨床応用には、低い生物学的利用能、毒性、耐性メカニズムを含む課題に対処する必要があります。
- 将来の戦略には、インテリジェントな抗がん剤開発のための高度なデリバリーシステム、精密医療、合成生物学が含まれます。
関連する概念動画
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Mitogens and the Cell Cycle
7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Metastasis
6.3K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K
Interactions Between Signaling Pathways
7.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K


